[FGFR2/3 in Urothelial Carcinoma]
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Turner N, Grose R
. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010; 10(2):116-29.
DOI: 10.1038/nrc2780.
View
2.
Touat M, Ileana E, Postel-Vinay S, Andre F, Soria J
. Targeting FGFR Signaling in Cancer. Clin Cancer Res. 2015; 21(12):2684-94.
DOI: 10.1158/1078-0432.CCR-14-2329.
View
3.
Liu X, Zhang W, Geng D, He J, Zhao Y, Yu L
. Clinical significance of fibroblast growth factor receptor-3 mutations in bladder cancer: a systematic review and meta-analysis. Genet Mol Res. 2014; 13(1):1109-20.
DOI: 10.4238/2014.February.20.12.
View
4.
Billerey C, Chopin D, Aubriot-Lorton M, Ricol D, Gil Diez de Medina S, van Rhijn B
. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol. 2001; 158(6):1955-9.
PMC: 1891972.
DOI: 10.1016/S0002-9440(10)64665-2.
View
5.
Pal S, Bajorin D, Dizman N, Hoffman-Censits J, Quinn D, Petrylak D
. Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results. Cancer. 2020; 126(11):2597-2606.
PMC: 7515773.
DOI: 10.1002/cncr.32806.
View